COMMUNIQUÉS West-GlobeNewswire

Seismic Therapeutic to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026
15/12/2025
WATERTOWN, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Seismic Therapeutic, Inc. , the machine learning immunology company, today announced that Jo Viney, Ph.D., Founder, President and Chief Executive Officer, will present [...]
NeuroSigma Completes $1 Million Investment into High-Volume Manufacturing Line for Second Generation Monarch eTNS® Device
15/12/2025
Armstrong Asia of Singapore selected as NeuroSigma’s manufacturing partner Investment led by Checkmate Capital as part of strategic partnership with Armstrong Asia First commercial units to be delivered in March 2026 [...]
MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13
15/12/2025
CARMEL, Ind., Dec. 15, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the [...]
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
15/12/2025
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Big Nova Gives $3 Million to Advance NMDP’s Mission and Help More Patients Receive Blood Stem Cell Transplants
15/12/2025
Family donations over a decade inspired by loved one’s life-saving transplant helped NMDP surpass $100 million campaign goal MINNEAPOLIS and ORLANDO, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NMDP SM announced today that [...]
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
15/12/2025
CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and [...]
FOXO TECHNOLOGIES INC. CEO SEAMUS LAGAN PROVIDES YEAR-END REVIEW TO SHAREHOLDERS
15/12/2025
WEST PALM BEACH, FL, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXO) (the “Company”), announces Chief Executive Officer Seamus Lagan has provided the following Year-End Review to shareholders: FOXO [...]
NetraMark Achieves Major FDA Milestone
15/12/2025
TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical [...]
PharmAla Biotech Australia Contracts with UK-based CDMO for Manufacture of ALA-002 Drug Substance
15/12/2025
TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
Sienna Announces December Dividend
15/12/2025
MARKHAM, Ontario, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
OKYO Pharma Announces Chairman and Founder Acquires Shares
15/12/2025
LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an [...]
TOMI Environmental Solutions Calls Upon Cruise Lines to Improve Decontamination and Adopt Hospital-Grade Technology Like SteraMist to Safeguard Passengers and Crew
15/12/2025
FREDERICK, Md., Dec. 15, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, is calling upon cruise lines to improve [...]
HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device
15/12/2025
Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the [...]
ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting
15/12/2025
37.8% of voting rights present or represented All resolutions were approved MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage [...]
Noom Enters Longevity Health Space with Proactive Health Microdose GLP-1Rx Program Designed to Help Millions Address the Biomarkers Most Linked to Future Disease
15/12/2025
New program pairs microdoses of GLP-1 medication with Noom’s powerful behavior-change program and at-home biomarker testing to track the health impact of combining GLP-1 therapy with healthy habits. PRINCETON, N.J., Dec [...]
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma
15/12/2025
Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years. Results suggest that nuclear GSK-3β expression may help identify patients most likely to respond to treatment of a [...]
SPR Reaches Milestone 50,000th Implant of the SPR® SPRINT® PNS System
15/12/2025
CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- SPR announced that it has reached 50,000 implants of the SPRINT ® PNS System, a significant milestone recognizing the impact of treatment for patients with 60-day peripheral [...]
BetaGlue Therapeutics obtient l’autorisation du ministère de la Santé belge pour mener un essai clinique portant sur YntraDose dans le traitement du cancer du pancréas localement avancé non résécable (uLA-PDAC)
15/12/2025
MILAN, 15 déc. 2025 (GLOBE NEWSWIRE) -- BetaGlue ® Therapeutics (« BetaGlue » ou la « Société »), une société italienne pionnière en oncologie au stade clinique, développant une solution innovante de radiothérapie pour [...]
BetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)
15/12/2025
MILAN, Dec. 15, 2025 (GLOBE NEWSWIRE) -- BetaGlue ® Therapeutics (“BetaGlue” or the “Company”), a pioneering Italian clinical-stage oncology company developing an innovative radiotherapy solution for the targeted [...]

Pages